Clinical Trials Browser

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT04471974 2025-07-22

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

61 enrolled

Genitourinary

Prostatic Neoplasms

NCT02955394 2025-07-09

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Phase 2 Active not recruiting

61 enrolled 12 charts

Breast

Breast Neoplasms

NCT02750358 2025-06-22

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Phase 2 Active not recruiting

50 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02446444 2025-05-30

ENZARAD

Phase 3 Active not recruiting

802 enrolled

Genitourinary

Prostatic Neoplasms

NCT04262154 2025-04-27

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

28 enrolled

Genitourinary

Prostatic Neoplasms

NCT02446405 2025-02-06

ENZAMET

Phase 3 Active not recruiting

1,125 enrolled

Genitourinary

Prostatic Neoplasms

NCT02685397 2024-12-04

PCS IX

Phase 2/3 Active not recruiting

102 enrolled

Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT03700099 2024-04-15

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

Phase 2 Active not recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

CASPAR

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

STEEL

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

ARACOG

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

PROTRACT

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

ENZARAD

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

ENZAMET

PCS IX

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide